DITOPHAL* IN THE TREATMENT OF LEPROSY

By K. F. Schaller,
Director of Princess Zenebe Work Hospital, Addis Ababa
and
C. Serhié,
Director of Institut Pasteur of Ethiopia

History

Davies and Driver (1956) investigated a claim that a mixture of certain thiol compounds prevented the development of tuberculosis in guinea-pigs (Del Pianto, 1950) and they discovered that the active principle involved was ethyl mercaptan. This property was possessed only by the ethyl homologue. They concluded that a derivative of ethyl mercaptan which was acceptable clinically and pharmaceutically and which liberated ethyl mercaptan in the body at the optimum rate should be effective against the mycobacterial diseases such as lupus, tuberculosis and leprosy. Ditophal was eventually chosen from about 400 ethyl mercaptan derivatives (Davies and Driver 1957).

The antituberculosis action of Ditophal is due to the release of ethyl mercaptan in the body, but neither compound shows any antituberculous activity in vitro. Both are, however, very effective against intracellular bacteria, ethyl mercaptan inhibiting the growth of M. tuberculosis in an infected monocyte culture at 10⁻⁷/ml. The action of the ethyl mercaptan derivatives is antagonised by the methyl analogues and it is thought that ethyl mercaptan acts by interfering with a metabolic pathway which involves methyl or methylthio groups and which is present either in the monocyte or is part of the specific metabolism of the bacillus in the monocyte. The metabolism of Ditophal and of ethyl mercaptan has been studied in laboratory animals using C¹⁴ and S³⁵-labelled drug and almost all the administered drug has been accounted for without finding a metabolite with antituberculous activity (Lawe 1960, Snow 1957).

Ditophal is effective in laboratory animals when administered either parenterally or orally but it is more effective by the former route. Oral dosing gives rise to ethyl mercaptan in the gastrointestinal tract and some of this escapes giving an unpleasant smell. The drug has the unique property of being rapidly absorbed through the skin, thus offering a novel method of parenteral administration in leprosy while avoiding the difficulties associated with injection. This method of administration appeared to be peculiarly suited to the treatment of leprosy and lupus vulgaris and NAGUIB and Robson

* Ditophal (Ethival I.C.I.)
(1956) had already shown it to be outstandingly active against intracorneal infections of murine leprosy in the mouse and it was completely non-toxic.

Chemistry
Chemically Ditophal is diethyl-dithiolisophthalate. It is a bland oily liquid with a garlic-like odour and has the unique property of high systemic activity after percutaneous absorption (following inunction into the skin). For the purpose of inunction Ditophal is presented in either cream or liquid formulation based on an active-agent content of 5 g. per dose and suitably perfumed to mask the intrinsic odour.

Previous Clinical Work in Leprosy
Ditophal began to be clinically used in 1957. Davey (1958) first reported his early impressions from Nigeria to the VIIth International Congress of Leprolology in Tokyo. Later (Davey and Hogerzil 1959, Davey 1959 & 1960) he published his experiences in greater detail and at a later stage of development. Ditophal was at first used alone, but later its greatest usefulness was found to lie in combined use with DDS or DPT (= SU 1906), where it materially reduced the period of time in which bacteriological and clinical improvement is obtained, compared with the length of time taken by these drugs, alone, to produce similar results. From experience, by trial and error, in a total of 133 patients Davey suggested that the best time to introduce Ditophal would be at a stage when full DDS maintenance dosage has been reached, and that the two drugs should then be given together for about 3 months.

Lechat (1959) in the Belgian Congo obtained equally favourable results in 28 lepromatous cases and found the cream readily accepted by all his patients.

Ross (1960) in Northern Nigeria found the bacterial index to
**Ditophal in the Treatment of Leprosy**

decline rapidly in 28 lepromatous and borderline cases, treated thrice weekly for 5 months.

Gabriel (1959-60), in 8 patients in Queensland, obtained results which made him regard Ditophal as an extremely useful drug, since its use considerably reduces the time required for clinical improvement to become apparent and for a negative phase of the disease to be reached.

Jamison and Palmer (1960) in 6 cases in Northern Nigeria, saw the bacilli disappear completely or almost completely, as well as finding marked histological improvement in leprous skin.

McGregor (1961) used Ditophal alone for 12 weeks in 29 lepromatous cases in Sarawak (twice-weekly inunctions) and saw clinical and bacteriological improvement well beyond the level experienced with other drugs in that length of time. This rate of improvement persisted after change-over to basic treatment.

Thangaraj and Thangaraj (1961) obtained excellent results in 6 fresh lepromatous cases at Purulia, India, who received Ditophal together with parenteral sulphone.

All reports to date are unanimous in pointing to the lack of any side effects and signs of toxicity.

**Personal Experiences**

A trial of Ditophal in combination with DDS was begun at the Princess Zenebe Work Hospital, Addis Ababa in September 1959. 19 patients were treated, of whom 18 were of the lepromatous type and 1 was tuberculoid. There was only 1 female in the group, this being a case suffering from lepromatous leprosy, aged 40, with a history of one year’s illness. The tuberculoid case was a man aged 26 with a history of two year’s illness before admittance. The remainder of the patients were all lepromatous cases, age varying from 12-46 years and the duration of the disease from 1-7 years.

Diagnosis was made on clinical, bacteriological, immunological and histo-pathological grounds. None of the patients had received any previous treatment. Laboratory tests (bacteriological smears) and histo-pathology were also carried out in the Pasteur Institute, Addis Ababa. The treatment consisted of DDS which was gradually built up to a maintenance dose of 700 mg. per week (100 mg. daily), maintenance dosage being reached at the end of the third month. At this stage the patients started to receive Ditophil ointment by inunction, one tube (containing 5 grammes active agent) thrice weekly at equally spaced intervals. 15 cases were treated for the full period of one year (52 weeks), 3 cases were treated for 36 weeks and 1 case for 37 weeks only. The total dosage of DDS for those on one year’s treatment amounted to 45 grammes and the total dosage of Ditophal to 156 tubes (780 g.).
Clinical details of cases

No. 20100—Male—20 years old.
Type of Disease: Lepromatous leprosy—4 years sick before admittance.
Lepromin: Negative. Tuberculin: Negative.
Weight: Slightly increased.
Hansen bacilli: On October, 1959 Nose: + + Skin: + + +
On October, 1960 Nose: Negative Skin: + +
Decrease of bacilli after 6 months of treatment. Lesions less active.
Patient feels better. General conditions improved.
Treatment: 32 weeks Total of Ditophal: 156 tubes (780 grammes) Total of D.D.S.: 54.6 G.

No. 20284—Male—20 years old.
Type of Disease: Lepromatous leprosy—5 years sick before admittance.
Lepromin: Negative. Tuberculin: Negative.
Weight: unchanged.
Hansen bacilli: On September, 1959 Nose: + + + Skin: + + +
On October, 1960 Nose: Negative Skin: + +
After 6 months considerable decrease of bacilli. Sedimentation rate improved.
Reaction after 3 months most probably due to D.D.S. Lepromatous lesions are flattened and less active. Patient feels better since 3 months trophic ulcer on left foot. Clinically improved.
Treatment: 32 weeks Total of Ditophal: 156 tubes (780 grammes) Total of D.D.S.: 54.5 G.

No. 18268—Male—20 years old
Type of Disease: Lepromatous leprosy—4 years sick before admittance.
Lepromin: Negative. Tuberculin: Negative.
Hansen bacilli: On September, 1959 Nose: + Skin: +
On October, 1960 Nose: Negative Skin: +
Weight increased by 5 kg.
Sedimentation rate: January, 1960—57/100 October, 1960—10/23
After 3 months of treatment patient suffers from leprosy reaction. Lepromatous lesions nearly disappeared. Patient feels better. General conditions improved.
Treatment: 31 weeks and 3 days Total of Ditophal: 155 tubes (765 grammes) Total of D.D.S.: 45.1 G.

No. 20148—Male—26 years old.
Type of Disease: Tuberculoid leprosy—2 years sick before admittance.
Weight: February, 60/9, 63 kg. October, 1960, 53 kg.
Hansen bacilli: On October, 1959 Nose: Negative January, 1960: + +
On October, 1960 Nose: Negative Skin: Negative
Sedimentation rate: January, 1960—10/33
Loss of sensibility in the right hand of muscular strength. Rheumatic pains which occurred after 10th month of treatment. Now, conditions improved again. Superficial ulcers on both feet which are under treatment. After 3 months patient showed reactionary phase with bacilli + +, which was followed by a general improvement.
Treatment: 31 weeks Total of Ditophal: 153 tubes (765 grammes) Total of D.D.S.: 45.4 G.

No. 20027—Male—23 years old.
Type of Disease: Lepromatous leprosy—5 years sick before admittance.
Lepromin: Negative. Tuberculin: Negative.
DITOPHAL IN THE TREATMENT OF LEPROSY

Hansen bacilli: On September, 1959: + + + +
Skin: + + + +

On October, 1960:
Nose: Negative
Skin: Negative

After 3 months treatment patient got reaction which is followed by decrease of bacilli. The sedimentation rate improved from 45/72 to 11/30. Patient feels much better but still complains of rheumatic pains on his legs and on his arms. Lepromatous lesions are flattened. Clinically improved.

TREATMENT: 52 weeks
Total of Ditophal: 156 tubes (780 grammes)
Total of D.D.S.: 45.6 G.

No. 20258—Male—22 years old.
Type of Disease: Lepromatous leprosy—6 years sick before admittance.
Lepromin: Negative. Tuberculin: 13 mm.
Weight: unchanged.
Hansen bacilli: On October, 1959: + + +
Skin: + + + +

On October, 1960:
Nose: Negative
Skin: Negative

Sedimentation rate increased. Leprosy reaction occurred and was controlled by usual treatment. Lepromatous lesions are less active. Patient clinically improved.

TREATMENT: 52 weeks
Total of Ditophal: 156 tubes (780 grammes)
Total of D.D.S.: 45.6 G.

No. 19835—Male—15 years old.
Type of Disease: Lepromatous leprosy—6 years sick before admittance.
Lepromin: Negative. Tuberculin: Negative.
Weight: 44 kg. now increased by 6 kg.
Hansen bacilli: On September, 1959: +
Skin: + + + +

On October, 1960:
Nose: Negative
Skin: Negative


TREATMENT: 52 weeks
Total of Ditophal: 156 tubes (780 grammes)
Total of D.D.S.: 45.6 G.

No. 19973—Male—33 years old.
Type of Disease: Lepromatous leprosy.
Lepromin: Negative. Tuberculin: 3 mm.
Hansen bacilli: On September, 1959: + + + +
Skin: + + + +

On October, 1960:
Nose: Negative
Skin: Negative

Sedimentation rate: not far from normal. Leprosy lesions on nose and skin disappeared; also the macular lesions on his back. Patient complains of disturbances in the sensibility on his left leg external surface. Clinically improved.

TREATMENT: 52 weeks
Total of Ditophal: 156 tubes (780 grammes)
Total of D.D.S.: 45.8 G.

No. 20275—Male—27 years old.
Type of Disease: Lepromatous leprosy—2 years sick before admittance.
Tuberculin: Negative. Lepromin: Negative.
Hansen bacilli: On October, 1959:
Skin: + + + +
Nose: + + +

On May, 1960:
Skin: +
Nose: + + +

Sedimentation rate: October, 1959 80/102. May, 1960 53/100
After 3 months reaction occurred followed by 2 relapses.
No marked improvement.

TREATMENT: 36 weeks
Total of Ditophal: 102 tubes (510 grammes)
Total of D.D.S.: 32.4 G.
No. 20126—Male—28 years old.
Type of disease: lepromatous leprosy—5 years sick before admittance.
Lepromin: Negative. Tuberculin: 15 mm.
Hansen bacilli: On October, 1959 Skin: +++
Nose: ++++
On October, 1960 Skin: Negative
Nose: Negative

After 3 months reaction most probably due to D.D.S. medication. Case is complicated by lymphogranuloma venereum like lesions. Lepra clinically improved.

TREATMENT: 52 weeks
Total of Ditoaphal: 156 tubes (780 grammes)
Total of D.D.S.: 45.6 G.

No. 20040—Male—28 years old.
Type of disease: lepromatous leprosy—7 years sick before admittance.
Tuberculin: Negative. Lepromin: Negative.
Hansen bacilli: On October 1959 Skin: +++
Nose: ++++
On July 1960 Skin: +++
Nose: ++++

After 3 months leprosy reaction, case did not show marked improvement.

TREATMENT: 36 weeks
Total of Ditoaphal: 108 tubes (540 grammes)
Total of D.D.S.: 32.4 G.

No. 20247—Male—45 years of age.
Type of disease: lepromatous leprosy—2 years sick before admittance.
Lepromin: Negative. Tuberculin: Negative.
Hansen bacilli: On October, 1960 Skin: ++++
Nose: ++++
On July, 1960 Skin: +++
Nose: Negative


Reaction after 3 months treatment—relapsed twice, patient is moderately improved.

TREATMENT: 36 weeks
Total of Ditoaphal: 120 tubes (600 grammes)
Total of D.D.S.: 32.4 G.

No. 19512—Male—54 years old.
Type of disease: lepromatous leprosy—6 years sick before admittance.
Lepromin: Negative. Tuberculin: Negative.
Hansen bacilli: On August, 1959 Skin: ++++
Nose: ++++
On November, 1960 Skin: Negative
Nose: Negative

Sedimentation rate: January, 1960 60/120. August, 1960 53/71

Lepra reaction after 3 months of treatment, patient increased weight, Ditoaphal was well tolerated, reaction most probably due to D.D.S. medication. Clinically improved.

TREATMENT: 52 weeks
Total of Ditoaphal: 156 tubes (780 grammes)
Total of D.D.S.: 45.6 G.

No. 20110—Male—27 years of age.
Type of disease: lepromatous leprosy 2/2 years sick before admittance.
Lepromin: Negative. Tuberculin: 10 mm.
Hansen bacilli: On October, 1959 Skin: +++
Nose: ++++
On February, 1960 Skin: +++
Nose: Negative

Patient tolerated well the treatment, but left the hospital after 5 months; therefore this case is not suitable for evaluation.

TREATMENT: 37 weeks
Total of Ditoaphal: 111 tubes (555 grammes)
Total of D.D.S.: 33.5 G.
DIT OPHAL IN THE TREATMENT OF LEPROSY

No. 201 S6—Female—40 years of age.
Type of disease: Lepromatous leprosy. 1 year sick before admitted.
Lepromin: Negative. Tuberculin: +10 mm.
Hansen bacilli: On October, 1959 Skin: +++
Note: ++
On October, 1960 Skin: +
Note: +
August 1960—reaction with two relapses. No considerable improvement.
TREATMENT: 52 weeks Total of Ditophal: 156 tubes (780 grammes) Total of D.D.S.: 45.6 G.

No. 201 S6—Male—18 years of age.
Type of disease: Lepromatous leprosy. 11 years sick before admittance.
Tuberculin: Negative. Lepromin: Negative.
Hansen bacilli: On October, 1959 Skin: +++
Note: +++
On October, 1960 Skin: Negative
Note: Negative
Sedimentation rate: October, 1959 21/52. October 1960 20/47.
After 3 months of treatment patient developed reaction, most probably due to D.D.S. Patient feels better, clinically improved.
TREATMENT: 52 weeks Total of Ditophal: 156 tubes (780 grammes) Total of D.D.S.: 45.6 G.

No. 20274—Male—46 years of age.
Type of disease: Lepromatous leprosy. 2 years sick before admittance.
Lepromin: Negative. Tuberculin Negative.
Hansen bacilli: On October, 1959 Skin: +++
Note: ++++
On October, 1960 Skin: +
Note: +
Sedimentation rate: October, 1959 95/120. October, 1960 130/155.
After 3 months patient suffered from reaction which relapsed 6 times—case is not improved.
TREATMENT: 51 weeks Total of Ditophal: 153 tubes (765 grammes) Total of D.D.S.: 45.5 G.

No. 20257—Male—12 years old.
Type of disease: Lepromatous leprosy. 1 year sick before admittance.
Tuberculin: Negative. Lepromin: Negative.
Hansen bacilli: On October, 1959 Skin: +++
Note: +
On October, 1960 Skin: Negative
Note: +
October, 1960 reaction besides treatment was well tolerated. Clinically improved.
TREATMENT: 52 weeks Total of Ditophal: 156 tubes (780 grammes) Total of D.D.S.: 45.6 G.

No. 20187—Male—15 years old.
Type of disease: Lepromatous leprosy. 2 years sick before admittance.
Lepromin: Negative. Tuberculin: Negative.
Hansen bacilli: On October, 1959 Skin: +
Note: +
On October, 1960 Skin: +
Note: +
Clinically no improvement.
TREATMENT: 52 weeks Total of Ditophal: 152 tubes (780 grammes) Total of D.D.S.: 45.6 G.
### Synopsis of Results with Ditophal in Lepromatous Cases

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Total Dosage gms.</th>
<th>Period of Treatment weeks</th>
<th>Bacteriological</th>
<th>Clinical</th>
<th>No. of Reactions</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>20275</td>
<td>510</td>
<td>36</td>
<td>unchanged</td>
<td>unchanged</td>
<td>3</td>
<td>Reaction after 3 months, followed by 2 relapses</td>
</tr>
<tr>
<td>20101</td>
<td>540</td>
<td>36</td>
<td>decrease</td>
<td>unchanged</td>
<td>1</td>
<td>Reaction after 3 months</td>
</tr>
<tr>
<td>20247</td>
<td>600</td>
<td>36</td>
<td>decrease</td>
<td>slightly improved</td>
<td>3</td>
<td>Reaction after 3 months, followed by 2 relapses</td>
</tr>
<tr>
<td>20100</td>
<td>780</td>
<td>32.4</td>
<td>decrease</td>
<td>improved</td>
<td>1</td>
<td>Reaction after 3 months</td>
</tr>
<tr>
<td>20110</td>
<td>780</td>
<td>33.3</td>
<td>decrease</td>
<td>not evaluated</td>
<td>0</td>
<td>Reaction after 3 months</td>
</tr>
<tr>
<td>20284</td>
<td>780</td>
<td>45.5</td>
<td>decrease</td>
<td>improved</td>
<td>1</td>
<td>Reaction after 3 months</td>
</tr>
<tr>
<td>18268</td>
<td>765</td>
<td>45.1</td>
<td>negative</td>
<td>improved</td>
<td>1</td>
<td>Reaction after 3 months</td>
</tr>
<tr>
<td>19835</td>
<td>780</td>
<td>45.6</td>
<td>negative</td>
<td>improved</td>
<td>0</td>
<td>Reaction after 3 months</td>
</tr>
<tr>
<td>19973</td>
<td>780</td>
<td>45.8</td>
<td>negative</td>
<td>improved</td>
<td>0</td>
<td>Reaction after 3 months</td>
</tr>
<tr>
<td>20027</td>
<td>780</td>
<td>45.6</td>
<td>negative</td>
<td>improved</td>
<td>1</td>
<td>Reaction after 3 months, followed by disappearance of bacteria</td>
</tr>
<tr>
<td>20258</td>
<td>780</td>
<td>45.6</td>
<td>negative</td>
<td>improved</td>
<td>1</td>
<td>Reaction after 3 months</td>
</tr>
<tr>
<td>19512</td>
<td>780</td>
<td>45.6</td>
<td>negative</td>
<td>improved</td>
<td>1</td>
<td>Reaction after 3 months</td>
</tr>
<tr>
<td>20156</td>
<td>780</td>
<td>45.6</td>
<td>decrease</td>
<td>unchanged</td>
<td>3</td>
<td>Reaction after 10 months' treatment, with 2 relapses</td>
</tr>
<tr>
<td>20186</td>
<td>780</td>
<td>45.6</td>
<td>negative</td>
<td>improved</td>
<td>1</td>
<td>Reaction after 3 months</td>
</tr>
<tr>
<td>20274</td>
<td>765</td>
<td>45.5</td>
<td>decrease</td>
<td>unchanged</td>
<td>7</td>
<td>Reaction after 3 months, with 6 relapses</td>
</tr>
<tr>
<td>20257</td>
<td>780</td>
<td>45.6</td>
<td>decrease</td>
<td>improved</td>
<td>1</td>
<td>Reaction after 12 months</td>
</tr>
<tr>
<td>20187</td>
<td>760</td>
<td>45.6</td>
<td>unchanged</td>
<td>unchanged</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>
Discussion of Results

Lepra Reactions Of the 18 lepromatous cases, details of which are consolidated in Table 1, only 5 did not experience reactions. Nine cases had one reaction, 4 patients had 3 or more reactions. In most cases, the reaction occurred at the end of three months’ treatment with DDS just at the time they were starting Ditophal inunction. Their reactions, therefore, may have been provoked by the DDS medication, although the contributory effect of Ditophal cannot be excluded.

Bacterial Examination Routine examinations of smears were carried out every two weeks. Reduction in the number of bacilli was seen in 16 cases and of these 9 cases progressed to negativity. Two cases showed no change in bacterial density but 1 of these 2 cases was only treated for 35 weeks. Histopathological findings (biopsies were carried out at intervals of 3 months) were in general agreement with the bacterial smears.

Clinical Evaluation Of the 14 lepromatous cases treated for 52 weeks, 12 cases showed marked improvement, the remaining 2 cases were not improved at all. Of the 4 lepromatous patients treated for only 36-37 weeks, 2 cases were not improved at all, 1 was only slightly improved, and the 4th could not unfortunately be evaluated as he was a defaulter. The lack of improvement in this group may have been due to the fact that these cases were treated for a shorter period of time than the group treated for 52 weeks.

It is interesting to note that 1 case of tuberculoid leprosy, additional to the 18 cases already described treated for 52 weeks, suffered from a “reactionary phase” with bacillary index positive, followed by bacterial negativity and good clinical improvement when the reaction subsided.

Tolerance The inunction was well tolerated by all except 2 patients who showed skin reactions of papular type in the area inuncted. On withdrawal of Ditophal inunction for a few days, the reactions cleared up with no special treatment and they did not recur when inunctions were started again. No other side effects were seen with the drug.

Summary

1. The observation period in this investigation, being slightly more than one year, does not permit any final conclusion as to the lasting effect of the treatment.

2. The results so far indicate that the combined treatment, using DDS and Ditophal, yields more rapid results than in cases when standard treatment is given with DDS alone.
3. No evidence of drug resistance has been encountered in our cases.

4. Patients in our series will continue to receive DDS alone when they have completed the year’s treatment of Ditophal and DDS, and these cases will continue to be kept under observation as out-patients.

5. We consider that further studies are desirable, in both in-patients and out-patients, with a view to finding which combination of standard drugs and Ditophal inunction and for how long, offers the best and most practicable way of treating the disease.

Acknowledgements

We are grateful to Health Officer Ato Zerihun Desta of Princess Zenebe Work Hospital, Addis Ababa, for assistance in following up our cases.

References


